Effects of Multidisciplinary Rehabilitation Enhanced with Neuropsychological Treatment on Post-Acute SARS-CoV-2 Cognitive Impairment (Brain Fog): An Observational Study.
SARS-CoV-2
brain fog
cognitive impairment
long COVID
neuropsychology
rehabilitation
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
12 May 2023
12 May 2023
Historique:
received:
08
04
2023
revised:
10
05
2023
accepted:
11
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Concentration and memory impairment (named "brain fog") represents a frequent and disabling neuropsychological sequela in post-acute COVID-19 syndrome (PACS) patients. The aim of this study was to assess whether neurocognitive function could improve after a multidisciplinary rehabilitation program enhanced with individualized neuropsychological treatment. A prospective monocentric registry of PACS patients consecutively admitted to our Rehabilitation Unit was created. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive impairment at admission and discharge. A total of sixty-four (64) PACS patients, fifty-six (56) of them with brain fog, were treated with a day-by-day individualized psychological intervention of cognitive stimulation (45 min) on top of a standard in-hospital rehabilitation program. The mean duration of the acute-phase hospitalization was 55.8 ± 25.8 days and the mean in-hospital rehabilitation duration was 30 ± 10 days. The mean age of the patients was 67.3 ± 10.4 years, 66% of them were male, none had a previous diagnosis of dementia, and 66% of the entire sample had experienced severe COVID-19. At admission, only 12% of the patients had normal cognitive function, while 57% showed mild, 28% moderate, and 3% severe cognitive impairment. After psychological treatment, a significant improvement in the MoCA score was found (20.4 ± 5 vs. 24.7 ± 3.7;
Identifiants
pubmed: 37239263
pii: brainsci13050791
doi: 10.3390/brainsci13050791
pmc: PMC10216015
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Intern Med. 2021 May;174(5):717-719
pubmed: 33284682
PLoS One. 2021 Feb 8;16(2):e0246590
pubmed: 33556127
Cell. 2022 Jul 7;185(14):2452-2468.e16
pubmed: 35768006
Neurology. 2013 Mar 12;80(11):1048-56
pubmed: 23390179
Int Psychogeriatr. 2012 Nov;24(11):1749-55
pubmed: 22687278
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
J Neurol. 2022 Jan;269(1):44-46
pubmed: 34143277
Clin Rev Allergy Immunol. 2023 Feb;64(1):66-74
pubmed: 33609255
Int J Environ Res Public Health. 2022 Jul 29;19(15):
pubmed: 35954630
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
G Ital Cardiol (Rome). 2020 Jun;21(6):417-420
pubmed: 32425184
J Intern Med. 2023 Feb;293(2):246-258
pubmed: 36478477
Am J Med Sci. 2023 May;365(5):472-474
pubmed: 36632867
Behav Res Ther. 2003 Dec;41(12):1489-96
pubmed: 14705607
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
J Med Virol. 2021 Feb;93(2):1175-1179
pubmed: 32841387
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Med Virol. 2022 Mar;94(3):979-984
pubmed: 34672377
Ann Neurol. 2008 Apr;63(4):494-506
pubmed: 18300306
Healthcare (Basel). 2022 Sep 24;10(10):
pubmed: 36292305
Alzheimers Dement. 2017 Aug;13(8):903-912
pubmed: 28216393
Sensors (Basel). 2022 Sep 01;22(17):
pubmed: 36081063
BMJ Open. 2022 Feb 11;12(2):e056366
pubmed: 35149572
Presse Med. 2022 Jun;51(2):104090
pubmed: 34718113
Disabil Rehabil. 2022 Nov;44(22):6833-6840
pubmed: 34559592
Cell. 2019 Jan 10;176(1-2):43-55.e13
pubmed: 30528430